Fig. 3

Biological impact of FTO in t(8;21) AML cells and AML1-ETO9a mice model. A–C Effects of forced expression of wild-type FTO (wt-FTO), mutant FTO (mut-FTO) or mock vectors (A); or FTO shRNA or scramble vectors (B), or FB23-2 treatment (C) on the proliferation of SKNO-1 and Kasumi-1 cells by CCK-8 assays. shNS: scramble shRNA. D Effects of forced expression or knockdown of FTO on colony-forming capacity of SKNO-1 cells. E The effect of FTO knockdown on differentiation of SKNO-1 cells. The percentage of CD11b⁺ cells was quantified (right panel). F Wright-Giemsa staining of SKNO-1 cells with or without FTO knockdown. G, H Effect of silencing the expression of FTO, confirmed by western blotting (G), on cell apoptosis in SKNO-1 and Kasumi-1 cells 72 h after siRNA transfection (H). I Western blotting of the Fto knockdown in AML1-ETO9a-driven AML mice cells. J, K Kaplan–Meier survival curves of AML1-ETO9a-driven AML mice (n = 10 for each group) with or without Fto knockdown (J) or treatment with DMSO or FB23-2 (K). L Hematoxylin and eosin (H&E) staining of liver (left panel) and spleen (right panel) of AML1-ETO9a-driven AML mice 7 weeks after transplantation. M–O Percentage of GFP⁺ AML1-ETO9a AML cells in the M peripheral blood (PB), N bone marrow (BM), and O spleen (SP) of the mice with or without Fto knockdown assessed by flow cytometric analysis. P–R Flow cytometric analysis of the distribution of anti-CD11b-stained GFP + AML1-ETO9a AML cells in PB (P), BM (Q), and SP (R) of mice with or without Fto knockdown